GAITHERSBURG, Md., Nov. 7, 2016 /PRNewswire/ -- Sirnaomics, Inc. ( www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announces today that an IND application for a Phase IIa clinical study of the company's leading siRNA therapeutic candidate, STP705 (Cotsiranib®) has received an approval from U.S. Food and Drug Administration. The approval of this "A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar" application comes just on the 30 th day after the company submission of the IND package. Sirnaomics lead product candidate, STP705, is an anti-fibrosis siRNA (small interfering RNA) therapeutic taking advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly diminish both fibrotic activity and inflammatory activity allowing for application in many disease states. "The green light from US FDA for Sirnaomics' first IND submission represents a major milestone for the company's mission in discovery and development of novel siRNA therapeutics for unmet clinical needs. Meanwhile, the STP705 first-in-man study can provide further evidence that our unique approaches for siRNA drug design and PNP formulation may hold great potential of success for RNAi therapeutics," said the Founder and CEO of the company, Dr. Patrick Y. Lu. "As a first-in-class siRNA therapeutics, STP705 anti-fibrosis and anti-inflammatory properties may be widely applied for other disease conditions." "The treatment of abnormal scarring is very important to our patients and the condition can result in both physical and psychological distress. There is a clear unmet medical need in the current treatment of patients with hypertrophic scar and it is very exciting to see new therapeutics such as STP705 enter into clinical study to address a problem that currently has very few effective treatment options," stated Dr. John Harmon, MD, Director of Surgical Research and Professor of Surgery at Johns Hopkins University in Baltimore, Maryland.